Observational studyBMC nephrology2025
Chronic kidney disease of unknown aetiology: a real-world study.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDiagnosis of rare chronic kidney disease (CKD) can be difficult with conventional diagnostic workup. When no diagnosis is identified, this is termed CKD of unknown aetiology (CKDUA). There are multiple benefits in obtaining a diagnosis in these cases. The advent and increasing availability of genetic testing in recent years has been a welcome additional diagnostic tool. In this study we aimed to determine the demographics and kidney related outcomes for a cohort of patients with CKDUA within the Salford Kidney Study (SKS).
methodsThe SKS is a single-centre, ongoing, prospective, observational cohort study of adult patients referred to the renal service at Salford Royal Hospital, UK. Within the SKS there are 398 patients with CKDUA. A group with diabetic kidney disease (DKD) was used as a comparator. An analysis was performed comparing these two groups with a particular focus on their demographics and kidney related outcomes.
resultsMedian age of the CKDUA cohort was 71.4 years, with 60.1% male and 96.2% White. There was advanced CKD at presentation (median eGFR 30 ml/min/1.73m2), with a 5-year mortality of 27.6%. When compared with the DKD cohort, the CKDUA cohort were older (71.4 years vs. 67.3 years, p < 0.001), had more equal sex distribution (male 60.1% vs. 68%, p < 0.009), had less advanced renal disease at presentation (eGFR 30 ml/min/1.73m2 vs. 26 ml/min/1.73m2, p < 0.001), and were less likely to progress to renal replacement therapy (14.1% vs. 28.2%, p < 0.001).
conclusionsCKDUA is difficult to manage: other than general supportive measures there is little else that can be offered. This study reports on a real-world cohort of patients with CKDUA and identifies the surprising finding that in comparison to a DKD cohort their outcomes are improved, with a significantly lower rate of progression to RRT. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.